Your survival rate for multiple myeloma is likely higher in earlier stages. Younger people often have better outcomes due to their resilience to intensive treatments. Advances in treatment have ...

Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health issues. The high relapse rates following initial treatments make the search for ...

The stage of diagnosis can impact survival rates. Patients with stage III multiple myeloma (MM) have an average life expectancy of 29 months, whereas patients with stages I and II disease survive on ...

Experts unpack new myeloma regimens—quadruplet induction, dual maintenance, earlier smoldering therapy—plus real-world access and cost hurdles. Welcome back to another AJMC Peer Exchange series. In ...

Using nationwide electronic health record (EHR) and cancer registry data from the VA Corporate Data Warehouse, we developed and validated a rule-based NLP algorithm to extract oncologist-determined MM ...

After a positive phase 3 trial, Johnson & Johnson hopes its Darzalex could become the first treatment option for patients with smoldering multiple myeloma, an early-stage form of the blood disorder. J ...

Staging, the process of finding out how advanced the cancer is, is very important because the treatment options and the outlook for recovery and survival depend on the stage of the cancer. Knowing all ...

Add Yahoo as a preferred source to see more of our stories on Google. A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020 in White Oak, Maryland. (Sarah ...

Pfizer reported that its multiple myeloma therapy Elrexfio met the primary goal in a late-stage study, significantly extending progression-free survival for patients who had received at least one ...

Explore how advancements in haematology and cancer treatment have transformed the prognosis for multiple myeloma patients ...